Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label randomized study of TAK-385 in Japanese patients with androgen deprivation treatment-naive nonmetastatic prostate cancer
jRCT2080222485Phase 1
- Sponsor
- Takeda
- Start
- May 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by Takeda.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080222485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222485.